170 related articles for article (PubMed ID: 8231249)
41. The induction of skin xenograft tolerance in rat-to-mouse combination could be affected by DFR mediating cells and antibodies against rat bone marrow cells as well as NK cells in the cyclophosphamide-induced tolerance system.
Nishimura Y; Eto M; Maeda T; Hiromatsu K; Nomoto K; Kong YY; Nomoto K
Immunobiology; 1995 Aug; 193(5):420-38. PubMed ID: 8522358
[TBL] [Abstract][Full Text] [Related]
42. Cyclophosphamide treatment of an SJL murine B-cell lymphoma increases the proportion of suppressive CD8+ over tumor-stimulatory CD4+ T-lymphocytes.
Wrone-Smith T; Cankovic M; VanBuren E; Lerman S
Leuk Res; 1993 Nov; 17(11):967-75. PubMed ID: 8231237
[TBL] [Abstract][Full Text] [Related]
43. In vivo growth inhibition of Ia+ lymphomas in SJL mice treated with I-As-reactive monoclonal antibody.
Alisauskas RM; Ponzio NM
Immunopharmacology; 1986 Aug; 12(1):1-9. PubMed ID: 2428770
[TBL] [Abstract][Full Text] [Related]
44. The Role of Regulatory B Cell-Like Malignant Cells and Treg Cells in the Mouse Model of BCL1 Tumor Dormancy.
BitMansour A; Pop LM; Vitetta ES
PLoS One; 2016; 11(12):e0167618. PubMed ID: 27959896
[TBL] [Abstract][Full Text] [Related]
45. Properties of reticulum-cell sarcomas in SJL/J mice. I. Proliferative response to tumor cells of T-derived lymphoid cells from normal mice.
Lerman SP; Chapman JM; Carswell EA; Thorbecke GJ
Int J Cancer; 1974 Dec; 14(6):808-16. PubMed ID: 4618550
[TBL] [Abstract][Full Text] [Related]
46. Tumor-cell vaccination induces tumor dormancy in a murine model of B-cell leukemia/lymphoma (BCL1).
Morecki S; Pugatsch T; Levi S; Moshel Y; Slavin S
Int J Cancer; 1996 Jan; 65(2):204-8. PubMed ID: 8567118
[TBL] [Abstract][Full Text] [Related]
47. Lymphoid cell populations in splenectomized and nonsplenectomized SJL/J mice bearing Hodgkin's disease-like reticulum cell sarcoma.
Brooks SP; Rich GA; Huh YS; Cooney DR
J Pediatr Surg; 1986 Dec; 21(12):1114-8. PubMed ID: 2947988
[TBL] [Abstract][Full Text] [Related]
48. The CD4 cell dependency of SJL/J B-cell lymphomas as a target for cyclophosphamide therapy.
Thrush GR; Placey JL; Valeriote FA; Lerman SP
Cancer Commun; 1989; 1(5):301-10. PubMed ID: 2518399
[TBL] [Abstract][Full Text] [Related]
49. B cell lymphomas of C57L/J mice; the role of natural killer cells and T helper cells in lymphoma development and growth.
Erianne1 GS; Wajchman2 J; Yauch3 R; Tsiagbe VK; Kim BS; Ponzio NM
Leuk Res; 2000 Aug; 24(8):705-18. PubMed ID: 10936423
[TBL] [Abstract][Full Text] [Related]
50. Properties of reticulum cell sarcomas in SJL/J mice. V. Nature of reticulum cell sarcoma surface antigen which induces proliferation of normal SJL/J T cells.
Ponzio NM; David CS; Shreffler DC; Thorbecke GJ
J Exp Med; 1977 Jul; 146(1):132-145. PubMed ID: 68988
[TBL] [Abstract][Full Text] [Related]
51. CD4 down regulation and raft dissociation by the non-depleting YTS177 antibody hinder murine T helper cell activities.
Wu CJ; Lu CH; Chen LC; Nguyen DT; Huang YS; Lin HH; Lin CY; Kuo ML
Biochem Biophys Res Commun; 2016 May; 473(4):973-979. PubMed ID: 27045081
[TBL] [Abstract][Full Text] [Related]
52. Opsonization of antitumor reactive lymphocyte in SJL/J mice bearing spontaneous or transplanted reticulum cell sarcomas (RCS).
Hutchinson IV; Roman J; Bonavida B
Adv Exp Med Biol; 1979; 121B():553-62. PubMed ID: 397761
[TBL] [Abstract][Full Text] [Related]
53. Regulation of immune responses in SJL and F1 hybrid mice by gamma-irradiated syngeneic lymphoma cells.
Katz IR; Nagase F; Bell MK; Ponzio NM; Thorbecke GJ
J Natl Cancer Inst; 1984 Jan; 72(1):125-32. PubMed ID: 6198549
[TBL] [Abstract][Full Text] [Related]
54. T helper cell activation in B-cell lymphomas.
Bosshart H
J Clin Oncol; 2002 Jun; 20(12):2904-5; author reply 2905. PubMed ID: 12065568
[No Abstract] [Full Text] [Related]
55. [Establishment of animal model of breast cancer dormancy].
Su GY; Liu YQ; Ren LR; Liu XF; Gu B; Dong JH; Gao J
Zhonghua Bing Li Xue Za Zhi; 2007 Nov; 36(11):760-3. PubMed ID: 18307882
[TBL] [Abstract][Full Text] [Related]
56. Cancer dormancy: isolation and characterization of dormant lymphoma cells.
Yefenof E; Picker LJ; Scheuermann RH; Tucker TF; Vitetta ES; Uhr JW
Proc Natl Acad Sci U S A; 1993 Mar; 90(5):1829-33. PubMed ID: 8446596
[TBL] [Abstract][Full Text] [Related]
57. Immunomodulatory effects of hemagglutinin- (HA-) modified A20 B-cell lymphoma expanded as a brain tumor on adoptively transferred HA-Specific CD4+ T cells.
Shichkin VP; Moriev RM
ScientificWorldJournal; 2014; 2014():165265. PubMed ID: 24693228
[TBL] [Abstract][Full Text] [Related]
58. In vivo biotinylation of the vasculature in B-cell lymphoma identifies BST-2 as a target for antibody-based therapy.
Schliemann C; Roesli C; Kamada H; Borgia B; Fugmann T; Klapper W; Neri D
Blood; 2010 Jan; 115(3):736-44. PubMed ID: 19903902
[TBL] [Abstract][Full Text] [Related]
59. Mathematical models of cancer dormancy.
Page K; Uhr JW
Leuk Lymphoma; 2005 Mar; 46(3):313-27. PubMed ID: 15621821
[TBL] [Abstract][Full Text] [Related]
60. Effect of cyclophosphamide on development of reticulum cell sarcoma in SJL/J mice.
Crispens CG
Experientia; 1982 May; 38(5):624-6. PubMed ID: 7047204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
